HUM · NYQ · Healthcare
Humana Inc.
Also onShortfallConsensus DriftCrosscheck
Implied value per share
USD 574.25
Market price
USD 386.22
Implied upside
+48.7%
5-year forecast · Perpetuity growth terminal value · Mid-year discounting · Base case
Value Per Share
Same forecast, different terminal treatment. Percentages vs price.
Forecast Cashflows
Reporting currency (USD). Outflows negative.
| Line | FY26 | FY27 | FY28 | FY29 | FY30 | CAGR |
|---|---|---|---|---|---|---|
| Revenue | USD 144.9bn | USD 162.0bn | USD 181.0bn | USD 202.3bn | USD 226.1bn | +11.8% |
| EBIT | USD 4.2bn | USD 4.7bn | USD 5.3bn | USD 5.9bn | USD 6.6bn | +11.8% |
| NOPAT | USD 3.3bn | USD 3.7bn | USD 4.2bn | USD 4.6bn | USD 5.2bn | +11.8% |
| Add depreciation & amortisation | USD 1.2bn | USD 1.3bn | USD 1.5bn | USD 1.6bn | USD 1.8bn | +11.8% |
| Less capital expenditure | USD -1.4bn | USD -1.6bn | USD -1.8bn | USD -2.0bn | USD -2.3bn | +11.8% |
| Less increase in working capital | USD 91.5m | USD 102.3m | USD 114.3m | USD 127.8m | USD 142.8m | -11.8% |
| Free cashflow to firm | USD 3.1bn | USD 3.5bn | USD 3.9bn | USD 4.4bn | USD 4.9bn | +11.8% |
| Discount factor | 0.9604 | 0.8858 | 0.8171 | 0.7536 | 0.6951 | - |
| Present value | USD 3.0bn | USD 3.1bn | USD 3.2bn | USD 3.3bn | USD 3.4bn | +3.1% |
| Present Value Of The Forecast | USD 16.0bn | |||||
Discount Rate
Source shown per component. All overridable above.
| Risk-free rate | 5.00% | US 10-year Treasury (^TNX) |
| Equity risk premium | 5.50% | Market assumption |
| Beta | 0.829 | Reported 0.745, pulled toward 1.0 (Blume) |
| Cost of equity | 9.56% | Risk-free + beta x equity risk premium |
| Cost of debt | 5.24% | Interest expense / average total debt |
| Market capitalisation | USD 46.4bn | 78.9% of capital |
| Total debt | USD 12.4bn | 21.1% of capital, book value as a proxy |
| Tax rate | 21.0% | Effective, capped at statutory |
| WACC | 8.42% | E/V x Re + D/V x Rd x (1 - t) |
Terminal Value
Perpetuity growth is intrinsic. The exit multiple defaults to the company's current EV/EBITDA, so it answers a different question - what the shares are worth if today's rating holds and EBITDA grows as forecast.
Perpetuity growth at 2.50%
74% of EV
- Forecast FCFF, final year
- USD 4.9bn
- Capex at depreciation, working capital in reinvestment
- USD 5.3bn
- Less reinvestment at g/ROIC (28.3% of NOPAT)
- USD -1.5bn
- Capitalised
- USD 3.8bn
- ROIC (reported)
- 8.8%
- Terminal value, undiscounted
- USD 65.9bn
- Terminal value, discounted
- USD 45.8bn
- Enterprise value
- USD 61.9bn
- Less net debt
- USD -7.5bn
- Equity value
- USD 69.4bn
Exit at 12.9x EBITDA
82% of EV
- Terminal value, undiscounted
- USD 108.4bn
- Terminal value, discounted
- USD 75.3bn
- Enterprise value
- USD 91.4bn
- Less net debt
- USD -7.5bn
- Equity value
- USD 98.9bn
Spread between methods: 35%.
Sensitivity
Value per share (USD) by discount rate and long-run growth.
| Long-run growth | |||||
|---|---|---|---|---|---|
| Discount rate | 1.50% | 2.00% | 2.50% | 3.00% | 3.50% |
| 6.42% | 770.52 | 794.63 | 824.42 | 862.38 | 912.70 |
| 7.42% | 651.56 | 661.90 | 673.98 | 688.39 | 706.02 |
| 8.42% | 567.00 | 570.48 | 574.25 | 578.40 | 583.04 |
| 9.42% | 507.77 | 509.32 | 510.88 | 512.43 | 513.99 |
| 10.42% | 463.05 | 464.40 | 465.75 | 467.10 | 468.45 |
Outlined: this model. Green text: above today's price of 386.22. Shading: distance from this model's own value.
Priced In
What each input would have to be to justify the current price, one at a time.
| Input | Model | Implied | Gap |
|---|---|---|---|
| Revenue growth, every year | 11.8% | 1.0% | -10.8pp |
| EBIT margin | 2.9% | 1.8% | -1.1pp |
| Discount rate | 8.4% | 12.8% | +4.4pp |
Live formulas, not pasted numbers - edit a driver and the workbook reprices.
Yahoo Finance and RBA data. General information, not advice. Methodology.